Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy

Background: Treatment of uterine serous carcinoma (USC) is challenging; effective treatment options for metastatic and recurrent disease are needed. Case: A 68-year-old woman with recurrent, metastatic, USC overexpressing HER2/neu experienced durable response to the antibody drug conjugate (ADC) tra...

Full description

Bibliographic Details
Main Authors: Blair McNamara, Stefania Bellone, Cem Demirkiran, Tobias Max Philipp Hartwich, Alessandro D. Santin
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:Gynecologic Oncology Reports
Subjects:
Trastuzumab deruxtecan
DS-8201a
Uterine serous carcinoma
HER2/neu
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578923000887

Internet

http://www.sciencedirect.com/science/article/pii/S2352578923000887

Similar Items